Anbiping released its 2026 interim report on August 28, 2026. During the reporting period, the company's total operating revenue was 172 million yuan, and net profit attributable to the parent company was 764,900 yuan. Net cash inflow from operating activities was 3.2979 million yuan, a decrease of 15.7147 million yuan compared with the same period last year, down 82.65 percent year on year. The company's latest asset-liability ratio was 9.32 percent, gross margin was 65.94 percent, ROE was 0.07 percent, and diluted earnings per share was 0.01 yuan. The number of shareholders was 7,700, and the top ten shareholders held 49.14 percent of the total share capital.
Guangzhou LBP Medicine Science & Technology Co LtdInterim report shows minimal net profit and significant cash flow decline, but no clear positive or negative driver.